Understanding the Burden of ACC Through the Eyes of Patients

Learn more about:
Related Clinical Trial
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Understanding the Burden of ACC Through the Eyes of Patients A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Study of Everolimus (RAD001) in Combination With Lenalidomide MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Dovitinib in Adenoid Cystic Carcinoma Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Study of RAD001 in Adenoid Cystic Carcinoma

Brief Title

Understanding the Burden of ACC Through the Eyes of Patients

Official Title

Understanding the Burden of ACC Through the Eyes of Patients

Brief Summary

      This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals
      affected by ACC who may know the results of molecular profiling of their tumor.

      Primary Objectives:

        -  To identify the specific burdens faced by patients with ACC

        -  To compare/contrast the burdens faced by patients with ACC at different disease stages
           (no evident disease, metastatic disease/watchful waiting, progressive disease)
    

Detailed Description

      This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals
      affected by ACC who may know the results of molecular profiling of their tumor.

      Primary Objectives:

        -  To identify the specific burdens faced by patients with ACC

        -  To compare/contrast the burdens faced by patients with ACC at different disease stages
           (no evident disease, metastatic disease/watchful waiting, progressive disease)

      Secondary Objectives:

        -  To assess QoL implication in patients living with ACC (Adenoid Cystic Carcinoma)

        -  To compare the burdens and QoL impacts in people living with ACC, with their tumors
           bearing Notch mutations or Notch Wild Type due to:

             -  Rate of disease progression

             -  Location of Metastases
    


Study Type

Observational


Primary Outcome

Key burdens related to the disease or treatments


Condition

Adenoid Cystic Carcinoma


Study Arms / Comparison Groups

 1
Description:  No evident disease

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

60

Start Date

January 11, 2021

Completion Date

March 31, 2022

Primary Completion Date

December 31, 2021

Eligibility Criteria

        Inclusion Criteria:

          1. Participant must be a person diagnosed with ACC who is 18 years or older

          2. For patients with metastatic disease; watchful waiting or progressive disease,
             participants must know the results of molecular profiling of their tumor

          3. Histologically-confirmed diagnosis of ACC with written proof of disease and molecular
             profile of tumor provided. This can be a note showing genetic diagnosis from a
             relevant testing laboratory, physician consult notes, a medical record of diagnosis,
             or any other single piece of documentation that connects your name/the patient's name
             with ACC.

          4. Able to read, write and understand English, Hebrew, Arabic, or Russian

          5. Able to grant informed consent

          6. Willing to participate in a 45-to-60-minute telephone interview, including follow up
             questions (if necessary)

        Exclusion Criteria:

        1. Inability to meet any of the inclusion criteria
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, (651)994-0510, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT04706845

Organization ID

AL Patient Burden 01


Responsible Party

Sponsor

Study Sponsor

Ayala Pharmaceuticals, Inc,

Collaborators

 Adenoid Cystic Carcinoma Research Foundation (ACCRF)

Study Sponsor

, , 


Verification Date

January 2021